118 related articles for article (PubMed ID: 25121176)
1. Axitinib: VEGF inhibition in advanced thyroid cancer.
Bagcchi S
Lancet Oncol; 2014 Jul; 15(8):e310. PubMed ID: 25121176
[No Abstract] [Full Text] [Related]
2. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
[TBL] [Abstract][Full Text] [Related]
3. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
4. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
5. Axitinib in the Treatment of Head and Neck Malignancies.
Swiecicki PL; Spector M; Worden FP
Curr Clin Pharmacol; 2016; 11(2):72-6. PubMed ID: 27188575
[TBL] [Abstract][Full Text] [Related]
6. Individualized dosing with axitinib: rationale and practical guidance.
Schmidinger M; Danesi R; Jones R; McDermott R; Pyle L; Rini B; Négrier S
Future Oncol; 2018 Apr; 14(9):861-875. PubMed ID: 29264944
[TBL] [Abstract][Full Text] [Related]
7. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
8. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE; Rosen LS; Vokes EE; Kies MS; Forastiere AA; Worden FP; Kane MA; Sherman E; Kim S; Bycott P; Tortorici M; Shalinsky DR; Liau KF; Cohen RB
J Clin Oncol; 2008 Oct; 26(29):4708-13. PubMed ID: 18541897
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
10. Axitinib (AG-013736).
Kelly RJ; Rixe O
Recent Results Cancer Res; 2010; 184():33-44. PubMed ID: 20072829
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Locati LD; Licitra L; Agate L; Ou SH; Boucher A; Jarzab B; Qin S; Kane MA; Wirth LJ; Chen C; Kim S; Ingrosso A; Pithavala YK; Bycott P; Cohen EE
Cancer; 2014 Sep; 120(17):2694-703. PubMed ID: 24844950
[TBL] [Abstract][Full Text] [Related]
12. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
[TBL] [Abstract][Full Text] [Related]
13. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
Kelly RJ; Rixe O
Target Oncol; 2009 Dec; 4(4):297-305. PubMed ID: 19876699
[TBL] [Abstract][Full Text] [Related]
14. [Dysthyroidism with anti-VEGF treatment, a class effect? about one case report].
Khouri C; Jean Bart E; Logerot S; Decker-Bellaton A; Bontemps H; Mallaret M
Therapie; 2014; 69(6):521-4. PubMed ID: 25293486
[TBL] [Abstract][Full Text] [Related]
15. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
J Hematol Oncol; 2015 Aug; 8():97. PubMed ID: 26239229
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
Kang S; Roh CR; Cho WK; Park KC; Yang KJ; Choi HS; Kim SH; Roh YJ
Curr Eye Res; 2013 Jan; 38(1):119-27. PubMed ID: 23013553
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of axitinib.
Patson B; B Cohen R; Olszanski AJ
Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):259-70. PubMed ID: 22248343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
